AstraZeneca Pharma India (NSE:ASTRAZEN) Other Long-Term Liabilities: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ASTRAZEN AstraZeneca Pharma India Ltd NSE:ASTRAZEN
90 GF Score
Price ₹7,906.50
GF Value ₹11,340.82
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is AstraZeneca Pharma India Other Long-Term Liabilities?

AstraZeneca Pharma India NSE:ASTRAZEN -0.50% 90 Other Long-Term Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:ASTRAZEN with a GF Score™ of 90/100 and a GF Value™ of ₹11,340.82 (Possible Value Trap). The stock has 6 warning signs investors should review.

AstraZeneca Pharma India's other long-term liabilities for the quarter that ended in Jun. 2026 was ₹0 Mil.

AstraZeneca Pharma India's quarterly other long-term liabilities increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹219 Mil) but then declined from Mar. 2026 (₹219 Mil) to Jun. 2026 (₹0 Mil).

AstraZeneca Pharma India's annual other long-term liabilities increased from Mar. 2024 (₹0 Mil) to Mar. 2025 (₹90 Mil) and increased from Mar. 2025 (₹90 Mil) to Mar. 2026 (₹219 Mil).

AstraZeneca Pharma India Other Long-Term Liabilities Related Terms

AstraZeneca Pharma India Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for AstraZeneca Pharma India's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Pharma India Other Long-Term Liabilities Chart

AstraZeneca Pharma India Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.00 0.00 90.00 219.20

AstraZeneca Pharma India Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 102.50 0.00 219.20 0.00
NSE:ASTRAZEN
90GF Score
AstraZeneca Pharma India Ltd NSE:ASTRAZEN
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Pharma India Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of ₹0 Mil mean?
AstraZeneca Pharma India (NSE:ASTRAZEN) has a Other Long-Term Liabilities of ₹0 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on AstraZeneca Pharma India and its competitors.
Is AstraZeneca Pharma India's Other Long-Term Liabilities too high?
AstraZeneca Pharma India's current Other Long-Term Liabilities is ₹0 Mil. Overall, AstraZeneca Pharma India has a GF Score™ of 90/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's Other Long-Term Liabilities compare to ZTS?
AstraZeneca Pharma India's Other Long-Term Liabilities of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on AstraZeneca Pharma India and its competitors. AstraZeneca Pharma India's current Other Long-Term Liabilities is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Possible Value Trap. The stock's GF Value™ is ₹11,340.82, compared to a current price of ₹7,906.50 — trading 30.3% below its estimated fair value. The current Other Long-Term Liabilities is ₹0 Mil. AstraZeneca Pharma India's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current Other Long-Term Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued. The current stock price of ₹7,906.50 is trading 30.3% below its estimated GF Value™ of ₹11,340.82. GuruFocus considers AstraZeneca Pharma India to be Possible Value Trap.

Key valuation signals for NSE:ASTRAZEN:

  • Other Long-Term Liabilities: ₹0 Mil
  • GF Value™: ₹11,340.82 vs. price of ₹7,906.50 (30.3% below fair value)
  • GF Score™: 90/100 with 6 warning signs

No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Pharma India Business Description

Other Exchanges 506820:India
Address Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
90GF Score

Get the complete analysis for NSE:ASTRAZEN

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹7,906.50
Price
₹11,340.82
GF Value